3 ms·
The reason is that this is an animal medicine so the study endpoints are much more lax than would be allowed for a medicine targeting a human indication.
by radicaldreamer 3y ago
The reason is that this is an animal medicine so the study endpoints are much more lax than would be allowed for a medicine targeting a human indication.
- s1artibartfast 3y agoPerhaps, there have been a few recent human approvals based solely on proxy endpoints as well. Imo, all such studies, human or animal should require large post approval RCTs